The article discusses the experimental drug NU-9, which has been approved for clinical trials for ALS, showcasing its potential to enhance neuron health in Alzheimer's models. The Northwestern study reveals that NU-9 addresses underlying mechanisms of protein misfolding that are common in neurodegenerative diseases rather than just treating symptoms. By targeting a shared pathway that prevents toxic protein buildup, NU-9 could potentially revolutionize treatment approaches for multiple neurological disorders, pending further human trials.
This drug is quite remarkable that it works in these multiple systems,
What our study demonstrates is that the same mechanism affects two totally different proteins in two totally different diseases.
Collection
[
|
...
]